[go: up one dir, main page]

DE602005007718D1 - Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms) - Google Patents

Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)

Info

Publication number
DE602005007718D1
DE602005007718D1 DE602005007718T DE602005007718T DE602005007718D1 DE 602005007718 D1 DE602005007718 D1 DE 602005007718D1 DE 602005007718 T DE602005007718 T DE 602005007718T DE 602005007718 T DE602005007718 T DE 602005007718T DE 602005007718 D1 DE602005007718 D1 DE 602005007718D1
Authority
DE
Germany
Prior art keywords
monoamin
vms
modulators
heterocyclic
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005007718T
Other languages
English (en)
Inventor
An Thien Vu
Paige Erin Mahaney
Stephen Todd Cohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE602005007718D1 publication Critical patent/DE602005007718D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005007718T 2004-03-30 2005-03-29 Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms) Expired - Fee Related DE602005007718D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55783104P 2004-03-30 2004-03-30
US56986104P 2004-05-11 2004-05-11
US11/091,291 US7414052B2 (en) 2004-03-30 2005-03-28 Phenylaminopropanol derivatives and methods of their use
PCT/US2005/010510 WO2005097761A1 (en) 2004-03-30 2005-03-29 Heterocyclic phenylaminopropanol derivatives as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms)

Publications (1)

Publication Number Publication Date
DE602005007718D1 true DE602005007718D1 (de) 2008-08-07

Family

ID=34964470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005007718T Expired - Fee Related DE602005007718D1 (de) 2004-03-30 2005-03-29 Heterocyclische phenylaminopropanolderivate als modulatoren der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)

Country Status (13)

Country Link
US (2) US7414052B2 (de)
EP (1) EP1730127B1 (de)
JP (1) JP2007531750A (de)
AR (1) AR048447A1 (de)
AT (1) ATE399158T1 (de)
AU (1) AU2005230899A1 (de)
BR (1) BRPI0509513A (de)
CA (1) CA2560966A1 (de)
DE (1) DE602005007718D1 (de)
PA (1) PA8628101A1 (de)
PE (1) PE20060163A1 (de)
TW (1) TW200538460A (de)
WO (1) WO2005097761A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1993321A (zh) * 2004-06-01 2007-07-04 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的3－氨基－1－芳基丙基吲哚类化合物
AU2006297414A1 (en) * 2005-09-29 2007-04-12 Wyeth 1- (1H- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
AR062481A1 (es) * 2006-08-24 2008-11-12 Wyeth Corp Proceso para preparar derivados de indolinona fenilaminopropanol
US7671238B2 (en) * 2006-10-04 2010-03-02 Wyeth Llc Arylamino-arylpropanolamine derivatives and methods of their use
CL2007003591A1 (es) * 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari
TW200904446A (en) * 2007-05-30 2009-02-01 Wyeth Corp Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
MX2011013324A (es) * 2009-06-10 2012-04-30 Abbott Gmbh & Co Kg Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
CN103384661B (zh) 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US4123543A (en) 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
CS175831B1 (de) 1974-12-17 1977-05-31
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH18686A (en) 1981-05-26 1985-08-29 Merck & Co Inc 1-(3 halo-2-pyridinyl) piperazine
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP0135905A3 (de) 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
CA1280421C (en) 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
DE69105501T2 (de) 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
US5648511A (en) 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5502047A (en) 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
WO1996005818A1 (en) 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
EP0921802A4 (de) 1996-03-25 2002-05-08 Lilly Co Eli Methoden zur behandlung von schmerzen
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
HUP0101404A3 (en) 1998-03-02 2002-09-30 Lilly Co Eli Fluoxetine hydrochloride for decreasing hot flashes
TW528754B (en) 1998-04-29 2003-04-21 Wyeth Corp Indolyl derivatibes as serotonergic agents
CA2336962A1 (en) 1998-07-13 2000-01-20 Alan Mueller Methods and compounds for treating depression and other disorders
NZ514612A (en) 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
PL196996B1 (pl) 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1272483A2 (de) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. Oxindole als faktor xa inhibitoren
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004509103A (ja) 2000-09-11 2004-03-25 セプレイコー　インコーポレイテッド モノアミン受容体及び輸送体のリガンドならびにその使用方法
BR0207157A (pt) 2001-02-12 2004-02-17 Wyeth Corp Sal de succinato de o-desmetil-venlafaxina
JP2004525940A (ja) 2001-03-29 2004-08-26 イーライ・リリー・アンド・カンパニー 火照りの処置のためのデュロキセチン
EP1266659A1 (de) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal im Verbindung mit Serotonine-hebenhemmer für die Behandlung des heissen Errötens
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
US6794385B2 (en) * 2001-08-08 2004-09-21 Pharmacia & Upjohn, S.P.A. Benzoxazine derivatives useful as integrin receptor antagonists
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037334A1 (en) 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
PL223471B1 (pl) 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
TW200402289A (en) 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
PL373956A1 (en) 2002-08-14 2005-09-19 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
US7345096B2 (en) 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US20050165082A1 (en) * 2003-12-16 2005-07-28 Wyeth Methods of treating vasomotor symptoms
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use

Also Published As

Publication number Publication date
TW200538460A (en) 2005-12-01
PE20060163A1 (es) 2006-04-17
AU2005230899A1 (en) 2005-10-20
JP2007531750A (ja) 2007-11-08
US7414052B2 (en) 2008-08-19
AR048447A1 (es) 2006-04-26
US7638512B2 (en) 2009-12-29
PA8628101A1 (es) 2005-11-25
US20080255102A1 (en) 2008-10-16
EP1730127A1 (de) 2006-12-13
US20050222142A1 (en) 2005-10-06
EP1730127B1 (de) 2008-06-25
WO2005097761A1 (en) 2005-10-20
ATE399158T1 (de) 2008-07-15
BRPI0509513A (pt) 2007-09-11
CA2560966A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE470660T1 (de) Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DK1879573T3 (da) Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
EP2101785A4 (de) Behandlung von trockenem auge
ATE489370T1 (de) Herstellung und verwendung von verbindungen als aspartylproteasehemmer
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE420881T1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
DE602005004268D1 (de) 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin-(ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee